scispace - formally typeset
Search or ask a question

Answers from top 8 papers

More filters
Papers (8)Insight
As new cancer antigens come to the forefront with novel RNA encapsulation and targeting techniques, RNA vaccines may prove to be a vital, safe and robust method to initiate patient-specific anti-tumor efficacy.
Journal ArticleDOI
22 Jun 2012-Vaccine
150 Citations
Possible drawbacks related to the cost and feasibility of manufacturing RNA vaccines are being addressed, increasing the likelihood that RNA-based vaccines will be commercially viable.
From this we conclude that sa-RNA is a promising platform for vaccines against viral diseases.
RNA vaccines can be produced in high amounts and have the same major advantages as DNA vaccines but lack the potentially harmful effect of DNA integration into the genome.
Naked, non-infectious, self-replicating RNA may be an excellent candidate for the development of new cancer vaccines.
These results demonstrate that genetically modified marker vaccines can be generated from small RNA viruses that lack non-essential genes.
This suggests that protein-based vaccines formulated using RNA adjuvant function as live-attenuated vaccines.
Therefore, RNA adjuvants have broad applicability and can be used with all conventional vaccines to improve vaccine efficacy qualitatively and quantitively.